Esteban James Philip G, Asgharpour Amon
Division of Gastroenterology and Hepatology, Medical College of Wisconsin, 8701 Watertown Plak Road, Milwaukee, WI 53226, USA; Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, Institute of liver medicine at Mount Sinai, 17 E 102nd St 8th floor, New York, NY 10029, USA.
Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, Institute of liver medicine at Mount Sinai, 17 E 102nd St 8th floor, New York, NY 10029, USA.
Gastroenterol Clin North Am. 2020 Mar;49(1):105-121. doi: 10.1016/j.gtc.2019.10.003.
Nonalcoholic fatty liver disease (NAFLD) is a common form of liver disease, associated with features of the metabolic syndrome. Nonalcoholic steatohepatitis (NASH), the aggressive subtype of NAFLD, can cause progressive fibrosis leading to cirrhosis. With the obesity epidemic, there is an increased health care burden from NASH, one of the most common causes of liver transplantation in the United States. There currently are no Food and Drug Administration-approved medical therapies for NASH. There exists a need for therapeutics to correct the drivers of NASH and to reverse or halt fibrosis progression. This article reviews pharmacologic therapeutics being developed to treat NASH.
非酒精性脂肪性肝病（NAFLD）是一种常见的肝脏疾病形式，与代谢综合征的特征相关。非酒精性脂肪性肝炎（NASH）是NAFLD的侵袭性亚型，可导致进行性纤维化，进而发展为肝硬化。随着肥胖症的流行，NASH带来的医疗保健负担不断增加，NASH是美国肝移植最常见的原因之一。目前美国食品药品监督管理局尚未批准用于治疗NASH的药物疗法。因此，需要开发能够纠正NASH驱动因素并逆转或阻止纤维化进展的治疗方法。本文综述了正在研发的用于治疗NASH的药物疗法。
